PO.6.135 Enpatoran: preclinical evidence supporting glucocorticoid dose reduction and phase II study design in patients with SLE and/or CLE (WILLOW)

• F Moreau,
• S Roy,
• M Khursheed,
• A Deshpande,
• C Vazquez-Mateo,
• EF Morand,
• VP Werth,
• A Bender,
• A Deshmukh,
• B Vaidyanathan,
• M Przetak,
• DR Pearson

Affiliations

F Moreau

1CHU Lille, institut de pharmacie, lille, france

S Roy

Antoine Béclère, 92140 Clamart, Clamart, France

M Khursheed

6Global Patient Safety, Merck Serono Ltd., an affiliate of Merck KGaA ~ Feltham ~ UK

A Deshpande

Department of Paediatrics, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India

C Vazquez-Mateo

3EMD Serono Research and Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, USA

EF Morand

3Monash Health, Department of Rheumatology, Clayton, Australia

VP Werth

3Corporal Michael J. Crescenz Veterans Affairs, Medical Centre Philadelphia PA, Philadelphia, USA

A Bender

Department of Neurology, University of Munich, Klinikum Grosshadern, Munich, Germany

A Deshmukh

3TIP Immunology, EMD Serono Research and Development institute, Inc., an affiliate of Merck KGaA ~ Billerica ~ USA

B Vaidyanathan

3TIP Immunology, EMD Serono Research and Development institute, Inc., an affiliate of Merck KGaA ~ Billerica ~ USA

M Przetak

3TIP Immunology, EMD Serono Research and Development institute, Inc., an affiliate of Merck KGaA ~ Billerica ~ USA

DR Pearson

8Department of Dermatology, University of Minnesota ~ Minnesota ~ USA